Cureteq is an asset management and biotechnology company developing innovative medicines based on a sophisticated artificial intelligence platform.
Cureteq leverages artificial intelligence to identify the optimal applications of a given molecule and to de-risk clinical development.
What we do
Cureteq is an asset management and biotechnology company developing innovative medicines based on a sophisticated artificial intelligence platform.
Cureteq leverages artificial intelligence to identify the optimal applications of a given molecule and to de-risk clinical development.
Cureteq est.
Nov 2021
Privately held
10+ Employees
Strategic partners
Innoplexus
Office in Zug
Portfolio company,
Oncoteq est. Apr 2022
Latest news
Meeting at J.P. Morgan 2024?
Looking for partnering or investment with Cureteq or Oncoteq? CEO Mads Dalsgaard, CFO Swati Mehta, and CBO Sarah Holland will be attending so please reach out to set up meeting in San Francisco
Oncoteq completes another in-licensing deal, adding a potential best-in-class CD30 antibody drug conjugate from Tubulis to its oncology pipeline
OncoteqAG (Oncoteq), a clinical stage biotech company specializing in novel and innovative cancer treatments, is expanding its development pipeline by in-licensing the potential best-in-class antibody …
Oncoteq further expands its pipeline, in-licensing a promising treatment for breast cancer
Oncoteq, a clinical stage biotech company specializing in innovative cancer treatments, today announces its second in-licensing deal as it obtains a world-wide exclusive license to a novel compound wi …
Shortcuts
Transforming drug development
We aim to transform drug development and drive assets beyond value inflection points by:
- Unlocking hidden value of unattended molecules through AI
- Combining agility and expertise in a lean structure
- Flexible partnering and financing model